Abigail Brooks, MA

At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.

HARMONY and SYMMETRY data show most early responders to efruxifermin 50 mg maintained fibrosis improvement through 96 weeks, with more responding late.

A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.

Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.

Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.

FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.

Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

The ASPIRED trial found immediate ECG monitoring in the ED did not reduce recurrent syncope but doubled arrhythmia detection and cut mortality.

H-ISDN missed its primary endpoint in H-HeFT, but a pooled meta-analysis found significant reductions in all-cause and cardiovascular death in HFrEF.

The China Rural Hypertension Control Program found a non-physician-led intensive blood pressure intervention reduced dementia risk by 15% over 7 years.

SHASTA-3 and SHASTA-4 found plozasiran cut triglycerides by roughly 80% and acute pancreatitis events by 78% in severe hypertriglyceridemia.

Phase 2b LUMINARA results showed the oral relaxin agonist AZD5462 improved echocardiographic measures of cardiac function in patients with chronic heart failure.

The Met-HeFT trial and a companion meta-analysis found metformin did not significantly improve cardiovascular outcomes in patients with HFrEF.

The REACT study found silent atherosclerosis in 57.1% of adults without known cardiovascular disease, a burden largely missed by the SCORE2 risk tool.

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

The ENRICH-AF trial found edoxaban did not significantly reduce stroke or systemic embolism but increased major bleeding in patients with AF and prior intracranial hemorrhage.

STAREE findings show atorvastatin reduced major cardiovascular events by 30% in older adults without known cardiovascular disease, but disability-free survival was unchanged.

An individual participant data meta-analysis found antihypertensive therapy reduced cardiovascular events only in patients with at least 80% medication adherence.

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

SURPASS-CVOT showed tirzepatide is non-inferior to dulaglutide for cardiovascular events in more than 13,000 adults with type 2 diabetes.

The ESC, ACC, AHA, and WHF jointly replaced numerical MI typing with primary, secondary, and procedure-related categories, announced at ESC Congress 2026.

CARDIO-TTRansform data presented at ESC 2026 showed no significant reduction in cardiovascular mortality or recurrent events with eplontersen vs placebo in ATTR-CM.

Experts discussed FCS diagnostic scoring tools, diagnostic delays, and new data on olezarsen and plozasiran for lowering triglycerides in a recent clinical forum.

A pair of clinical forums examined new CKM staging, SGLT2 and MRA trial data, and the barriers delaying heart failure treatment.

The FDA approved a 12-hour OTC combination of guaifenesin, dextromethorphan, and naproxen for cold and influenza symptom relief.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

Plozasiran cut triglycerides up to 81% and reduced acute pancreatitis events in phase 3 SHASTA-3, SHASTA-4 trials for severe hypertriglyceridemia.

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.